Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib for papulopustular rosacea
2025-524496-23-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in papulopustular rosacea comparing Remibrutinib with Placebo (2 arms). Primary endpoint: Absolute change from baseline in facial inflammatory lesion count at Week 16. Planned start Oct 2026; status: authorised.
02
Drugs
remibrutinib
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on 2025-524496-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524496-23-00.